Vasculitis & polymyalgia rheumatica
Switching from intravenous to subcutaneous infliximab in Behçet's disease: feasibility, safety and early outcomes
Authors' conclusion
Switching stable BD patients from IV to SC-IFX was feasible and well-tolerated, with preliminary signals suggesting that disease control may be maintained in many patients.
Study context
- Population
- Adults with Behçet's disease (BD) (International Criteria for Behçet's Disease (ICBD)) in stable remission on IV-IFX for ≥12 months, with ≥6 months of SC-IFX, four Italian referral centresmedian age 44 years
- Participants
- 10 adults
- Exposure
- Switch from IV-IFX to SC-IFX
- SC-IFXn = 10
- Outcome
- Feasibility on remission maintenance, safety and patient acceptance after switching from IV to SC-IFX
Methodological detailsmulticentre, observational, four Italian referral centres, Median IV-IFX duration before switch 83.5 [IQR 24.7-145.3] months
- Multicentre
- Observational
- Four Italian referral centres
- Median IV-IFX duration before switch 83.5 [IQR 24.7-145.3] months
Main finding
As reported in the abstract
Remission maintenance after switch · median follow-up 15.5 [IQR 7.50-19.00] months
Relapses (both patients resumed intravenous (IV) therapy)
2
Prednisone use decreased
from 50% to 20%
Observational data: associations, not effects.
Further findings
Patient acceptance (Self-Injection Assessment Questionnaire (SIAQ))
- Feedback among respondents generally positive, high satisfaction on ease of use, self-confidence and quality of life with subcutaneous (SC) administration
Safety
Infections
- Infections occurred in three patients
- 3
Significant systemic adverse events
- No significant systemic adverse events were reported
Original publication
Switching from intravenous to subcutaneous infliximab in Behçet's disease: feasibility, safety and early outcomes. Clin Exp Rheumatol. Published 18 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →